Back to the main directory
EarningsReview / Equity
- EQUITA SIM: SARAS (HOLD; Unchanged) - 4Q22 Results by Equita Sim
- Murray International Trust - Things looking good for MYI’s shareholders by Edison Investment Research
- Novo Nordisk - Sales growth looks set to beat expectations by Danske Bank Equity Research
- H2: Net interest income potential materializing by BNP Paribas Exane
- PA Good Doctor (1833 HK) by HSBC
- Stronger Rafale deliveries coming with lower RandD costs by BNP Paribas Exane
- Towngas Smart Energy (1083 HK) by HSBC
- Share gains through housing pains by BNP Paribas Exane
- Restoring operating resilience by BNP Paribas Exane
- Assa Abloy (Buy, TP: SEK315.00) - A ‘win-win’ and sector top pick by DnB Markets
- Aker Solutions (Buy, TP: NOK45.00) - ‘Fixed-price’ opportunity by DnB Markets
- Itaú BBA on Fleury: Soft 4Q22 Results, as Expected by Itau
- Itaú BBA on Vivara: Best in Class 4Q22 by Itau
- Itaú BBA on Bemobi: Uninspiring Growth but Nice Profitability in 4Q22; We Need to See an Acceleration for a Re-Rating by Itau
- Itaú BBA on Wiz: Better-Than-Expected 4Q22 Results by Itau
- 18th Basic Materials Conference Guide by BNP Paribas Exane
- 2023 BNPP Exane Global Cloud Scanner Survey by BNP Paribas Exane
- Waking the AI Sleeping Giant by BNP Paribas Exane
- Building a bright future by BNP Paribas Exane
- AFRY - Restoring profitability by Danske Bank Equity Research
- Dear Mr Asam, by BNP Paribas Exane
- CTT - Strong end to the year on the back of Financial Services; reiterating Buy by JB Capital Markets
- Protection, Inspection, Expectation by BNP Paribas Exane
- Koskisen - Buy/EUR 9: Panels drive earnings as sawnwood bottoms out by Nordea
- INVEST SECURITIES - VALBIOTIS : 2022 sans surprise, année 2023 charnière - ACHAT, OC 10,3€ (vs 10,6€) by Invest Securities